[ CAS No. 156478-71-6 ] {[proInfo.proName]}

Name: 156478-71-6|2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)acetic acid|98%
Brand: Ambeed
SKU: A106857
Price: 6.0 USD
Availability: InStock
Rating: 91 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 156478-71-6

Structure of 156478-71-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 156478-71-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 156478-71-6 ]

SDS Specification

Alternatived Products of [ 156478-71-6 ]

Product Details of [ 156478-71-6 ]

CAS No. :	156478-71-6	MDL No. :	MFCD02682402
Formula :	C₁₁H₂₀N₂O₄	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	WZBHMXRBXXCEDD-UHFFFAOYSA-N
M.W :	244.29	Pubchem ID :	2735642
Synonyms :

Calculated chemistry of [ 156478-71-6 ]

Physicochemical Properties

Num. heavy atoms :	17
Num. arom. heavy atoms :	0
Fraction Csp3 :	0.82
Num. rotatable bonds :	5
Num. H-bond acceptors :	5.0
Num. H-bond donors :	1.0
Molar Refractivity :	69.98
TPSA :	70.08 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-9.04 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.23
Log Po/w (XLOGP3) :	-1.76
Log Po/w (WLOGP) :	-0.14
Log Po/w (MLOGP) :	0.22
Log Po/w (SILICOS-IT) :	-0.2
Consensus Log Po/w :	0.07

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	0.08
Solubility :	297.0 mg/ml ; 1.21 mol/l
Class :	Highly soluble
Log S (Ali) :	0.8
Solubility :	1550.0 mg/ml ; 6.36 mol/l
Class :	Highly soluble
Log S (SILICOS-IT) :	-0.35
Solubility :	110.0 mg/ml ; 0.45 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.41

Safety of [ 156478-71-6 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 156478-71-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 156478-71-6 ]
Downstream synthetic route of [ 156478-71-6 ]

[ 156478-71-6 ] Synthesis Path-Upstream 1~3

1
[ 209667-59-4 ]
[ 156478-71-6 ]

Yield	Reaction Conditions	Operation in experiment
76%	With sodium hydroxide In methanol; water at 20℃; for 2 h;	b) 2-(4-(tert-Butoxycarbonyl) piperazin-l-yl) acetic acidTo a solution of the compound of Intermediate Example 23(a) (1.5 g, 5.51 mmol) in methanol (10 ml) was added aqueous solution of NaOH (0.8 g, 22.0 mmol, 4 eq). The mixture was stirred at RT for 2 h. The mixture was concentrated and extracted as in Intermediate Example 5(c). The solvent was distilled off to give the product in 76 percent yield (1 g). LC-MS (ESI): Calculated mass: 244.29; Observed mass: 145.1 [M- Boc+H] ⁺ (rt: 0.102 min).
76%	With water; sodium hydroxide In methanol at 20℃; for 16 h;	To a solution of the compound of Intermediate Example 23(a) (1.5 g, 5.51 mmol) in methanol (10 ml) was added aqueous solution of NaOH (0.8 g, 22.0 mmol, 4 eq). The mixture was stirred at RT for 2 h. The mixture was concentrated and extracted as in Intermediate Example 5(c). The solvent was distilled off to give the product in 76percent yield (1 g). LC-MS (ESI): Calculated mass: 244.29; Observed mass: 145.1 [M-Boc+H]⁺ (rt: 0.102 min).
38%	Stage #1: With sodium hydroxide; water In methanol for 4 h; Stage #2: With citric acid In water	A solution of 4-ethoxycarbonylmethyl-piperazine-l-carboxylic acid tert-butyl ester (1.3 g, 4.78 mmol) in methanol (50 ml) was treated with NaOH (IN, 10 ml, 10 mmol) and stirred for 4 h. The mixture is concentrated and the residue is adjusted to pH 6 with 5percent citric acid solution. The mixture is extracted with ethyl acetate, dried over sodium sulfate and concentrated to give 4-carboxyrnethyl-piperazine-l-carboxylic acid tert-butyl ester, 445 mg (38percent) as a white solid. ESI MS m/z 1179 (M + H⁺); ¹H NMR (400 MHz, CDCl₃) δ 3.80-3.60 (m, 4 H), 3.42 (s, 2H), 3.10-2.84 (m, 4H), 1.24 (s, 9H).

37%

With potassium hydroxide; water In tetrahydrofuran at 22℃; for 2 h;

Intermediate 27 (a) (3.6 G, 13.2 MMOL) and a 5percent aqueous KOH solution (90 mL, 80.0 MMOL) were stirred in tetrahydrofuran (30 mL, 0.44 M) at 22 °C for 2 hours. The volatiles were removed in vacuo and treatment with strongly acidic DOWEX-50 (WX8-200), elution with ammonium hydroxide (1.0 N), and treatment with AMBERLITET" CG-50 afforded Intermediate 27 (b) (1.2 G) in 37percent yield. APOS;H-NMR (d6-DMSO) : 8 3.35-3. 31 (m, 4H), 3.21 (s, 2H), 2.52-2. 41 (m, 4H), 1.39 (s, 9H).

Reference： [1] Patent: WO2013/53983, 2013, A1, . Location in patent: Page/Page column 42
[2] Patent: US2015/11548, 2015, A1, . Location in patent: Paragraph 0169
[3] Patent: WO2008/8480, 2008, A2, . Location in patent: Page/Page column 60
[4] Patent: WO2004/63198, 2004, A1, . Location in patent: Page 92-93
[5] Patent: US2018/185362, 2018, A1, . Location in patent: Paragraph 0801; 0804; 0805

2
[ 7646-93-7 ]
[ 209667-59-4 ]
[ 156478-71-6 ]

Reference： [1] Patent: US5977139, 1999, A,

3
[ 57260-71-6 ]
[ 156478-71-6 ]

Reference： [1] Patent: US2015/11548, 2015, A1,
[2] Patent: US2018/185362, 2018, A1,
[3] Patent: WO2013/53983, 2013, A1,

[ 156478-71-6 ] Synthesis Path-Downstream 1~38

1
[ 156478-71-6 ]
[ 1004988-04-8 ]

Yield	Reaction Conditions	Operation in experiment
100%	With caesium carbonate; In methanol; water; at 20℃; for 0.0833333h;	To a solution of amino acid (23.7 mmol) in MeOH (20 mL) and water (10 mL) was added cesium carbonate (11.8 mmol) in small portions. The resulting solution was stirred at rt for 5 min, concentrated in vacuo to remove MeOH, frozen, and then lyophilized to give a white powder. Toluene was added to this powder, and the suspension was concentrated in vacuo, and the resulting white powder was dried in a vacuum oven at 50 C. overnight to give a quantitative yield of cesium salt as a white powder.

Reference： [1]Patent: US2008/27053,2008,A1 .Location in patent: Page/Page column 11; 12

2
[ 156478-71-6 ]
[ 1001315-30-5 ]
[ 1001315-38-3 ]

Yield	Reaction Conditions	Operation in experiment
78%	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; triethylamine; In N,N-dimethyl-formamide; for 2h;	A solution of 2-methyl-6-nitro-2-(4-piperazin-l-yl-phenoxymethyl)- 2,3-dihydro-imidazo[2,l-b]oxazole (200 mg, 0.34 mmol) and 4-carboxymethyl- piperazine-1 -carboxylic acid tert-butyl ester (136 mg, 0.55 mmol) in DMF is treated with TBTU (179.8 mg, 0.55 mmol), triethyl amine (0.23 ml, 1.65 mmol) and stirred for 2 h. <n="63"/>The mixture is diluted with water and extracted with ethyl acetate. The organic layer is dried over sodium sulfate and concentrated. The residue is purified by preparative TLC (10% methanol in dichloromethane to give 4-(2-{4-[4-(2-methyl-6-nitro-2,3-dihydro- imidazo[2, 1 -b]oxazol-2-ylmethoxy)-phenyl]-piperazin- 1 -yl} -2-oxo-ethyl)-piperazine- 1 - carboxylic acid tert-butyl ester as yellow oil (152 mg, 78%). ESI MS m/z 585 (M + H+); 1H NMR (400 MHz, CDCl3) delta 8.01 (s, IH), 6.83 (d, J = 8.4 Hz, 2H), 6.78 (d, J = 8.4 Hz, 2H), 4.48 (d, J = Hz, ), 4.18 (d, J = Hz, IH), 4.14-4.02 (m, 2H), 3.82-3.71 (m, 4H), 3.56-3.38 (m, 4H), 2.91 (s, 2H), 2.52-2.42 (m, 4H), 1.75-1.62 (m, 4H), 1.42 (s, 9H).

Reference： [1]Patent: WO2008/8480,2008,A2 .Location in patent: Page/Page column 60-61

3
[ 209667-59-4 ]
[ 156478-71-6 ]

Yield	Reaction Conditions	Operation in experiment
76%	With sodium hydroxide; In methanol; water; at 20℃; for 2h;	b) 2-(4-(tert-Butoxycarbonyl) piperazin-l-yl) acetic acidTo a solution of the compound of Intermediate Example 23(a) (1.5 g, 5.51 mmol) in methanol (10 ml) was added aqueous solution of NaOH (0.8 g, 22.0 mmol, 4 eq). The mixture was stirred at RT for 2 h. The mixture was concentrated and extracted as in Intermediate Example 5(c). The solvent was distilled off to give the product in 76 % yield (1 g). LC-MS (ESI): Calculated mass: 244.29; Observed mass: 145.1 [M- Boc+H] + (rt: 0.102 min).
76%	With water; sodium hydroxide; In methanol; at 20℃; for 16h;	To a solution of the compound of Intermediate Example 23(a) (1.5 g, 5.51 mmol) in methanol (10 ml) was added aqueous solution of NaOH (0.8 g, 22.0 mmol, 4 eq). The mixture was stirred at RT for 2 h. The mixture was concentrated and extracted as in Intermediate Example 5(c). The solvent was distilled off to give the product in 76% yield (1 g). LC-MS (ESI): Calculated mass: 244.29; Observed mass: 145.1 [M-Boc+H]+ (rt: 0.102 min).
38%		A solution of 4-ethoxycarbonylmethyl-piperazine-l-carboxylic acid tert-butyl ester (1.3 g, 4.78 mmol) in methanol (50 ml) was treated with NaOH (IN, 10 ml, 10 mmol) and stirred for 4 h. The mixture is concentrated and the residue is adjusted to pH 6 with 5% citric acid solution. The mixture is extracted with ethyl acetate, dried over sodium sulfate and concentrated to give 4-carboxyrnethyl-piperazine-l-carboxylic acid tert-butyl ester, 445 mg (38%) as a white solid. ESI MS m/z 1179 (M + H+); 1H NMR (400 MHz, CDCl3) delta 3.80-3.60 (m, 4 H), 3.42 (s, 2H), 3.10-2.84 (m, 4H), 1.24 (s, 9H).

37%	With potassium hydroxide; water; In tetrahydrofuran; at 22℃; for 2h;	Intermediate 27 (a) (3.6 G, 13.2 MMOL) and a 5% aqueous KOH solution (90 mL, 80.0 MMOL) were stirred in tetrahydrofuran (30 mL, 0.44 M) at 22 C for 2 hours. The volatiles were removed in vacuo and treatment with strongly acidic DOWEX-50 (WX8-200), elution with ammonium hydroxide (1.0 N), and treatment with AMBERLITET" CG-50 afforded Intermediate 27 (b) (1.2 G) in 37% yield. 'H-NMR (d6-DMSO) : 8 3.35-3. 31 (m, 4H), 3.21 (s, 2H), 2.52-2. 41 (m, 4H), 1.39 (s, 9H).
	With water; lithium hydroxide; In tetrahydrofuran; methanol; at 0 - 20℃; for 3h;	To a stirred solution of tert-butyl 4-(2-ethoxy-2- oxoethyl) piperazine-i-carboxylate (2.8 g, 10.29 mmol) in a mixture of THF: MeOH: water (3:1:1, 30 mE) was addedlithium hydroxide (1.29 g, 30.8 mmol) at 00 C. The reactionwas gradually warmed to room temperature andstirred for 3 h. Afier consumption of starting material (byTEC), the volatiles were concentrated under reduced pres()sure. Then the residue was acidified to pH 4-5 with 5% citricacid solution and extracted with EtOAc (2x100 mE). Thecombined organic extracts were dried over anhydrousNa2SO4 and concentrated under reduced pressure to obtain2-(4-(tert-butoxycarbonyl) piperazin-i -yl) acetic acid (200mg, crude) as yellow oil used in the next step without furtherpurification.10805] EC-MS: m/z 245.1 [M-H] at 1.06 RT (71.81%purity).

Reference： [1]Patent: WO2013/53983,2013,A1 .Location in patent: Page/Page column 42
[2]Patent: US2015/11548,2015,A1 .Location in patent: Paragraph 0169
[3]Patent: WO2008/8480,2008,A2 .Location in patent: Page/Page column 60
[4]Patent: WO2004/63198,2004,A1 .Location in patent: Page 92-93
[5]Patent: US2018/185362,2018,A1 .Location in patent: Paragraph 0801; 0804; 0805

4
[ 141-91-3 ]
[ 156478-71-6 ]
[ 666852-88-6 ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; N-(3-dimethylaminopropyl)-N-ethylcarbodiimide; N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; for 16h;	EDC (1.18g, 6.15 mmol) was added to a stirred solution of N-Boc-piperazine acetic acid [(L.] [OOG,] 4.10 mmol), 2,6-dimethylmorpholine [(605GEL,] 4.92 mmol), [3-HYDROXYBENZOTRIAZOLE] (0.836g, 6.15 mmol), and diisopropylethylamine (2. [14ML,] 12.31 mmol) in DCM (30ml) at ambient temperature under nitrogen. After stirring for 16h the reaction was quenched by the addition of water [(20ML).] The phases were separated and the organics were washed with sat. brine [(20ML),] dried and evaporated to dryness under reduced pressure. The residue was purified by chromatography on silica, eluting with 0-10% MeOH/DCM to give 40 as a white solid (1. [31G).] MS-ESI: 342 [(M++H).] [1H NMR (CDC13)] 1.20 (d, 6H), 1.46 (s, 9H), 2.34 (dd, 1H), 2.40-2. 55 (m, 4H), 2.75 (dd, 1H), 3.10 (d, [1H),] 3.27 (d, 1H), 3.35-3. 60 (m, 6H), 3.94 (d, 1H), 4.40 (d, 1

Reference： [1]Patent: WO2004/18480,2004,A1 .Location in patent: Page 101

5
[ 280-13-7 ]
[ 156478-71-6 ]
[ 666852-94-4 ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; N-(3-dimethylaminopropyl)-N-ethylcarbodiimide; N-ethyl-N,N-diisopropylamine; In dichloromethane; for 16h;	EDC (1.18g, 6.15 mmol) was added to a stirred solution of [N-BOC-PIPERAZINE] acetic acid [(L.] [OOG,] 4.10 mmol), 8-oxa-3-aza-bicyclo [3.2. 1. ] octane (0.556g, 4.92 mmol), 3-hydroxy benzotriazole (0.836g, 6.15 mmol), and diisopropylethylamine (2. 14ml, 12.31 mmol) in DCM (20 ml) at ambient temperature under nitrogen. After stirring for 16h the reaction was quenched by the addition of water [(20ML).] The phases were separated and the organics were washed with sat. brine [(20ML),] dried and evaporated to dryness under reduced pressure. The residue was purified by chromatography on silica, eluting with 0-10% MeOH/DCM to give 46 as a white solid (0.780g). MS-ESI: 340 (M++H). [1H NMR (CDC13)] 1.45 (s, 9H), 1.80-2. 00 (m, 4H), 2.30-2. 58 (m, 4H), 2.85-3. 04 (m, [2H),] 3.25 (d, 1H), 3.30-3. 57 (m, 3H), 3.78 (d, 1H), 4.12 (d, 1H), 4.36 (d, 3H).

Reference： [1]Patent: WO2004/18480,2004,A1 .Location in patent: Page 103-104

6
[ 156478-71-6 ]
[ 59702-07-7 ]
C₁₆H₂₈N₄O₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With dmap; N-(3-dimethylaminopropyl)-N-ethylcarbodiimide; In dichloromethane; at 20℃; for 16h;	A mixture [OF N-BOC-4-PIPERAZINE-ACETIC] acid hydrochloride dihydrate (0.4g, 1.26 mmol), N- methyl-2-piperazinone (0.194g, [1.] [7MMOL),] DMAP [(L.] [OG,] 8.2 mmol) and EDC (0.4g, 2. [1MMOL)] in dichloromethane (60 ml) was stirred under a nitrogen atmosphere for 16h. The reaction mixture was washed with a [L.] OM aq. citric acid solution (2 x 50ml), sat. sodium bicarbonate solution, the organics separated, dried and evaporated to dryness under reduced pressure. The residue was purified by chromatography on silica eluting with 10- 20percent MEOH/EtOAc to give 66 (0.3g) as a solid foam. MS-ESI: 341 [(M++H).] [1H NMR (DMSOD6)] 1.50 (s, 9H), 2.48 (m, 4H), 2.97 (s, 3H), 3.22-3. 56 (m, 8H), 3.78 3.90 (2t, 2H), 4.09 4.29 (2s, 2H).

Reference： [1]Patent: WO2004/18480,2004,A1 .Location in patent: Page 111

Yield	Reaction Conditions	Operation in experiment
		B. 4-[(1,1-Dimethylethoxy)carbonyl]-1-piperazineacetic acid To a solution of the title A compound (16.5 g, 49.3 mmol) in methanol (200 ml) was added palladium on carbon (1.0 g) and the mixture hydrogenated for one hour. The catalyst was filtered off by suction and the filtrate evaproated n vacuo to provide 9.78 g of the title B product.

8
[ 7646-93-7 ]
[ 209667-59-4 ]
[ 156478-71-6 ]

Yield	Reaction Conditions	Operation in experiment
	With lithium hydroxide; In tetrahydrofuran; chloroform; water; ethyl acetate;	Combine 1-t-butoxycarbonyl-4-carboethoxymethylpiperazine (20.8 g, 76.5 mmol) and lithium hydroxide (6.71 g, 160 mmol) in tetrahydrofuran (100 mL) and water (100 mL). After 60 minutes, concentrate in vacuo to give a solid. Combine the solid and water, extract with diethyl ether. Combine the aqueous layer and a 1M aqueous solution of potassium hydrogensulfate (160 mL). Extract three times with chloroform. Evaporate the aqueous layer to give a solid. Triturate the solid repeatedly with warm ethyl acetate and isopropanol and filter. Evaporate each triturate to give solids. Combine the solids obtained by evaporation of the triturates, dissolve in chloroform and evaporate to remove solvent. Dry in vacuo at 50 C. to give 1-t-butoxycarbonyl-4-carboxymethylpiperazine as a solid, mp: 195-197 C. IR (KBr) nmax 3007, 2934, 1691, 1631, 1479, 1453, 1427, 1415, 1393, 1366, 1301, 1283, 1232, 1209, 1177, 1139, 1084 cm-1; 1 H NMR (CDCl3) ppm 3.71 (br s, 4 H), 3.56 (br s, 2 H), 3.12 (br s, 4 H), 1.46 (s, 9 H); 13 C NMR (CDCl3) ppm 169.10, 154.13, 80.70, 58.49, 52.38, 28.25; MS (CI/NH3) m/z 245 (M+1)+.

Reference： [1]Patent: US5977139,1999,A

9
[ 156478-71-6 ]
1-methyl-7-piperazin-1-ylmethyl-1H-indole-2-carboxylic acid-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-amide dihydrochloride [ No CAS ]
[ 1215385-53-7 ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE XXI Tert-butyl 4-(2-{4-[2-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenylcarbamoyl)-1-methyl-1H-indol-7-ylmethyl]-piperazin-1-yl}-2-oxo-ethyl)-piperazine-1-carboxylate 110 mg tert-butyl 4-carboxymethyl-piperazine-1-carboxylate are dissolved in 2 ml N,N-dimethylformamide, combined with 135 mg O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium-tetrafluoroborate (TBTU) as well as 270 mul N,N-diisopropyl-ethylamine (DIEA) and stirred for 20 minutes. Then 200 mg 1-methyl-7-piperazin-1-ylmethyl-1H-indole-2-carboxylic acid-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-amide dihydrochloride are added, the mixture is stirred for 12 hours at ambient temperature and then divided between water and ethyl acetate. The organic phase is washed with saturated aqueous sodium chloride solution and dried on magnesium sulphate. The solvents are eliminated in vacuo and the residue is chromatographed on silica gel (dichloromethane/(methanol/conc. ammonia 9:1) 99:1 to 90:10). Yield: 160 mg (64% of theory) HPLC (method 1): retention time=2.79 min. Mass spectrum (ESI+): m/z=754 [M+H]+

Reference： [1]Patent: US2011/269737,2011,A1 .Location in patent: Page/Page column 50

10
[ 57260-71-6 ]
[ 156478-71-6 ]

Reference： [1]Patent: US2015/11548,2015,A1
[2]Patent: US2018/185362,2018,A1
[3]Patent: WO2013/53983,2013,A1

11
(5-fluoro-pyridin-2-yl)-hydrazine [ No CAS ]
[ 156478-71-6 ]
[ 1443242-99-6 ]

Yield	Reaction Conditions	Operation in experiment
80%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 16h;	a. 4-[N'-(5-fluoro-pyridin-2-yl)-hydrazinocarbonylmethyl]- erazine-l-carboxylic acid tert-butyl ester (Intermediate 7a) EDC (543 mg, 2.83 mmol) was added portionwise to a solution of 2-(4- Boc- l-piperazinyl)acetic acid (576 mg, 2.36 mmol), 5-fluoro-2-hydrazinyl- pyridine (for reference procedure see WO2010022076; 0.30 g, 2.36 mmol) and HOBt (32 mg, 0.24 mmol) in dry DCM (15 mL) at T and stirred for 16 h. The solution was diluted with DCM (20 mL), washed with water (2 x 20 mL) and dried (Na2SO4). The solvent was evaporated to give the title compound as an off-white solid (667 mg, 80%). LCMS (Method 1): Rt 1.99 min, m/z 354 [MH+].

Reference： [1]Patent: WO2013/83604,2013,A1 .Location in patent: Page/Page column 140

12
(5-fluoro-pyridin-2-yl)-hydrazine [ No CAS ]
[ 156478-71-6 ]
[ 1443243-00-2 ]

Reference： [1]Patent: WO2013/83604,2013,A1

13
[ 156478-71-6 ]
(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]ctane-2-carbohydrazide [ No CAS ]
C₂₅H₃₆N₆O₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
93%	With N-ethyl-N,N-diisopropylamine; HATU; In dichloromethane; at 20℃;	Example 49: Synthesis of(2S,5R)-7-oxo-2-(5-(piperazin-l-ylmethyl)-l,3,4-oxadiazol-2-yl)- -diaz.abicyclo[3.2.1 loctan-6-yl hydrogen sulfate (Compound 777) ESI-MS (EI+, m/z): 389.2. 1H NMR (300 MHz, D20) delta 4.77 (d, / = 6.4 Hz, IH), 4.16 (br s, IH), 3.96 (s, 2H), 3.22 - 3.11 (m, 5H), 2.88 (d, / = 12.3 Hz, IH), 2.85 - 2.76 (m, 4H), 2.31 - 2.02 (m, 3H), 1.98 - 1.78 (m, IH).

Reference： [1]Patent: WO2013/149121,2013,A1 .Location in patent: Page/Page column 124

14
[ 156478-71-6 ]
C₂₅H₃₄N₆O₅ [ No CAS ]

Reference： [1]Patent: WO2013/149121,2013,A1

15
[ 156478-71-6 ]
C₁₈H₂₈N₆O₅ [ No CAS ]

Reference： [1]Patent: WO2013/149121,2013,A1

16
[ 156478-71-6 ]
[ 1613334-62-5 ]
C₃₀H₃₀BrN₅O₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; triethylamine; at 20℃; for 3h;	Example 72 (Z)-3-(2-(5-bromo-l-(2-(piperazin-l-yl)acetyl)-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile hydrochloride (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile (150mg), 2- (4-(tert-butoxycarbonyl)piperazin-l-yl)acetic acid (121mg), PyBOP (310mg), Triethylamine (Oi l ml) , reaction time 3 hours at RT. Then HC1 37% (0.165 ml), DMF (2ml) 2 hours at reflux. Aspect of the product: yellow solid. (Yield: 46%) APCI-MS: (M+H)+ = 504 1H NMR (300 MHz, DMSO-d6) delta ppm 9.36 (s, 1H), 8.44 - 8.33 (m, 2H), 8.31 (d, J = 1.8 Hz, 1H), 8.21 (d, J = 1.8 Hz, 1H), 8.03 (dd, J = 8.7, 2.1 Hz, 1H), 7.96 (s, 1H), 7.68 (dd, J = 8.9, 1.8 Hz, 1H), 7.39 (d, J = 8.8 Hz, 1H), 4.62 (s, 2H), 3.98 (s, 3H), 3.26 (d, J = 17.6 Hz, 8H).

Reference： [1]Patent: WO2014/86964,2014,A1 .Location in patent: Page/Page column 93-94

17
[ 156478-71-6 ]
[ 1430727-51-7 ]
tert-butyl 4-(2-((2',4'-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1'-biphenyl]-3-yl)amino)-2-oxoethyl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
25%	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; for 16h;	a) To a solution of the compound of Example 2(a) (100 mg, 0.249 mmol) in DMF was added <strong>[156478-71-6]2-(4-(tert-butoxycarbonyl)piperazin-1-yl)acetic acid</strong> (121 mg, 0.498 mmol, 2 eq.) followed by HATU (190 mg, 0.498 mmol, 2 eq.) and DIPEA (0.17 ml, 0.996 mmol, 4 eq.). The mixture was stirred for 16 h and quenched and extracted as in Example 1(d). The solvent was distilled off to give the crude residue which was purified by preparative HPLC to give the product in 25% yield (25 mg).

Reference： [1]Patent: US2015/11548,2015,A1 .Location in patent: Paragraph 0601

18
[ 156478-71-6 ]
[ 1430727-51-7 ]
N-(2',4'-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1'-biphenyl]-3-yl)-2-(piperazin-1-yl)acetamide [ No CAS ]

Reference： [1]Patent: US2015/11548,2015,A1

19
[ 156478-71-6 ]
[ 593-51-1 ]
tert-butyl 4-[(methylcarbamoyl)methyl]piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
500 mg	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20℃; for 24h;	To a solution of <strong>[156478-71-6]2-[4-[(tert-butoxy)carbonyl]piperazin-1-yl]acetic acid</strong> (500 mg, 2.05 mmol) in DMF (20 mL) was added methanamine hydrochloride (406 mg, 6.01 mmol), DIEA (793 mg, 6.14 mmol) and HATU (1.17 g, 3.08 mmol). The resulting solution was stirred for 12 h at room temperature for 12 h. Water (50 mL) was added. The resulting solution was extracted with DCM (*3) and the organic layers combined. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with 5% MeOH in DCM. This resulted in 500 mg of tert-butyl 4-[(methylcarbamoyl)methyl]piperazine-1-carboxylate as yellow oil. LCMS (Method 25) [M+H]+=258.0, RT=0.52 min.

Reference： [1]Patent: US2015/336962,2015,A1 .Location in patent: Paragraph 0937

20
[ 156478-71-6 ]
C₂₀H₂₂F₃N₅O₂ [ No CAS ]
C₃₁H₄₀F₃N₇O₅ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
36%		Under N2 at room temperature, 4-dimethylaminopyridine (lOmg; 0.08mmol), 1 [Bis(dimethylamino)methylene]- 1H- 1 ,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (1.35g; 3.6mmol) and diisopropylethylamine (1.3mL; 7.1mmol) were added to a solution of 4-Boc-l-piperazineacetic acid (0.35g; 1.4mmol) in DMF (18 mL). After 10 minutes, intermediate 81a (0.6g; 1.4mmol) was added and the solution was stirred at room temperature for 64 hours. The solution was poured out into cooled water and EtOAc was added. The organic layer was extracted, washed with water, dried with MgSC and evaporated to dryness. The resulting residue was mixed with another crude coming from a reaction performed on 200mg of intermediate 8 la. A purification was then performed via silica gel chromatography (Stationary phase: irregular SiOH 15-40muiotaeta, Mobile phase: 96% DCM, 4% MeOH, 0.1% NH4OH). The fractions containing the product were mixed and the solvent was evaporated to afford 440 mg of intermediate 105 (36%).

Reference： [1]Patent: WO2016/97359,2016,A1 .Location in patent: Page/Page column 141

21
[ 156478-71-6 ]
[ 104-86-9 ]
tert-butyl 4-{2-[(4-chlorophenyl)methoxy]-2-oxoethyl}piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 18h;	2- {4 - [(tert-butoxy) carbonyl] piperazin-1-yl} acetic acid (500 mg)(4-chlorophenyl) methanamine (0.27 mL),EDC (420 mg),HOBt (297 mg)Was dissolved in dichloromethane (4 mL)And the mixture was stirred at room temperature for 18 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction solution,It was extracted with dichloromethane and washed with saturated brine.The organic layer was dried over sodium sulfate,By distilling off the solvent under reduced pressuretert-butyl 4- {2 - [(4-chlorophenyl) methoxy] -2 oxoethyl} piperazine- 1 - carboxylate812 mg as a crude product.The obtained tert-butyl 4- {2 - [(4-chlorophenyl)Methoxy] -2 oxoethyl} piperazine-1-carboxylate (812 mg) was dissolved in dichloromethane (4 mL)Trifluoroacetic acid (2 mL) was added dropwise, and the mixture was stirred at room temperature for 5 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction solution, and the mixture was extracted with dichloromethane and washed with saturated brine. The organic layer was dried over sodium sulfate,By distilling off the solvent under reduced pressure(4-chlorophenyl) methyl 2- (piperazin-1-yl) acetate 384 mg (yield 73%)

Reference： [1]Patent: JP2017/171619,2017,A .Location in patent: Paragraph 0022; 0024

22
[ 156478-71-6 ]
C₂₃H₂₉N₃O₄ [ No CAS ]

Reference： [1]Patent: WO2018/53446,2018,A1

23
[ 156478-71-6 ]
C₄₃H₄₆N₄O₇ [ No CAS ]

Reference： [1]Patent: WO2018/53446,2018,A1

24
[ 156478-71-6 ]
C₂₃H₃₂N₄O₆ [ No CAS ]

Reference： [1]Patent: WO2018/53446,2018,A1

25
[ 156478-71-6 ]
methyl (S)-2-(2-(4-(acetyl-L-prolyl)piperazin-1-yl)acetamido)-3-(4-(benzyloxy)phenyl)propanoate [ No CAS ]

Reference： [1]Patent: WO2018/53446,2018,A1

26
[ 156478-71-6 ]
[ 34805-17-9 ]
tert-butyl (S)-4-(2-((3-(4-(benzyloxy)phenyl)-1-methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
91%		DIEA (0.534 mL, 3.065 mmol), and HATU (0.560 g, 1.472 mmol) were added into a solution of 4-N-Boc-piperazineacetic acid (0.300 g, 1.223 mmol) in anhydrous DMF (7 mL) at rt and stirring for 3 mi H-Tyr(bzl)-OMeHC1 was added into the mixture and stirred for 18 h and concentrated under reduced pressure. The resulting residue was dissolved in EtOAc and washed with Sat. NH4OH (2 x 20 mL) and sat. NaHCO3 (2 x 20 mL). Purification by flash column chromatography using EtOAc/Hexane (1:1- 100:0) as eluent afforded SR1-090 as a white foam (0.569 g, 91%). HPLC: >98% [tR = 9.6 mm,60% MeOH, 40% water (with 0.1% TFA), 20 minj. ?HNMR(400 MHz, DMSO-d6) oe 7.90 (d, J= 8.1 Hz, 1H), 7.47-7.28 (m, 5H), 7.11 (d,J= 8.6 Hz, 2H), 6.96-6.89(m, 2H), 5.06(s, 2H),4.54 (td, J 8.7, 5.2 Hz, 1H), 3.64 (s, 3H), 3.24 (m, 4H), 3.03 (dd, J= 13.9, 5.2 Hz, 1H), 2.96(m, 1H), 2.91 (m, 1H), 2.83 (d, J= 15.5 Hz, 1H), 2.30-2.11 (m, 4H). HRMS (ESI+): m/zC28H37N306 (M+H) 512.2748; m/z C28H37N3O6Na (M+Na) 534.2568. HPLC-MS (ESI+): m/z512.4 [100%, (M+H)j.

Reference： [1]Patent: WO2018/53446,2018,A1 .Location in patent: Page/Page column 38; 39

27
[ 156478-71-6 ]
2-(4-(5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)piperazin-1-yl)-1-(pyrrolidin-1-yl)ethan-1-one [ No CAS ]

Reference： [1]Patent: US2018/185362,2018,A1

28
[ 123-75-1 ]
[ 156478-71-6 ]
tert-butyl 4-(2-oxo-2-(pyrrolidin-1-yl)ethyl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
100 mg	With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In dichloromethane; at 20℃; for 16h;Inert atmosphere;	j0806] To a stirred solution of 2-(4-(tert-butoxycarbonyl)(15 mE) under an inert atmosphere was added pyrrolidinepiperazin-i-yl) acetic acid (500 mg, 2.04 mmol) in CH2C12(0.2 mE, 2.45 mmol), HATU (1.1 g, 3.07 mmol) andethyldiisopropylamine (1.5 mE, 8.19 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. Afier consumption of starting material (byTEC), the reaction mixture was diluted with water (30 mE)and extracted with CH2C12 (2x30 mE). The combinedorganic extracts were dried over anhydrous Na2SO4 andconcentrated under reduced pressure. The crude materialpurified by silica gel column chromatography (eluent:2% MeOH/CH2C12) to afford tert-butyl 4-(2-oxo-2-(pyrro-lidin-i -yl)ethyl) piperazine-i -carboxylate (100 mg, 0.33nmol, 16%) as brown solid.10807] ?H NMR (500 MHz, DMSO-d5): oe 3.43 (t, J=6.7Hz, 2H), 3.31 (s, 2H), 3.29-3.25 (m, 4H), 2.43 (brs, 4H),1.87-1.82 (m, 2H), 1.78-1.71 (m, 2H), 1.39 (s, 9H), 1.29-i.23 (m, 2H)1

Reference： [1]Patent: US2018/185362,2018,A1 .Location in patent: Paragraph 0801; 0806; 0807

29
[ 156478-71-6 ]
C₂HF₃O₂*C₁₀H₁₉N₃O [ No CAS ]

Reference： [1]Patent: US2018/185362,2018,A1

30
[ 156478-71-6 ]
Piperazin-1-yl-acetic acid (acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester [ No CAS ]

Reference： [1]Patent: US2008/27053,2008,A1

31
[ 156478-71-6 ]
4-[(Acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methoxycarbonylmethyl]-piperazine-1-carboxylic acid tert-butyl ester [ No CAS ]

Reference： [1]Patent: US2008/27053,2008,A1

32
[ 156478-71-6 ]
4-[1-(acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-ethoxycarbonylmethyl]-piperazine-1-carboxylic acid tert-butyl ester [ No CAS ]
4-[1-(acetyl-{(R)-3-[3-fluoro-4-(2-methyl-2,6-dihydro-4H-pyrrolo[3,4c]pyrazol-5-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-ethoxycarbonylmethyl]-piperazine-1-carboxylic acid tert-butyl ester [ No CAS ]

Reference： [1]Patent: US2008/27053,2008,A1

33
[ 156478-71-6 ]
tert-butyl 4-((8-chloroimidazo[1,5-a]pyrazin-3-yl)methyl)piperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/46711,2019,A2

34
[ 156478-71-6 ]
tert-butyl 4-((1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)methyl)piperazine-1-carboxylate [ No CAS ]

Reference： [1]Patent: WO2019/46711,2019,A2

35
[ 156478-71-6 ]
[ 771581-15-8 ]
tert-butyl 4-(2-(((3-chloropyrazin-2-yl)methyl)amino)-2-oxoethyl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
67%		A mixture of 4-Boc-1-piperazineacetic acid (2.7 g, 11.1 mmol), HOBT (1.6 g, 12.0 mmol), EDC.HC1 (2.3 g, 12.0 mmol) and DIPEA (4.0 mL, 25 mmol) ) in DMF (30 mL) was stirred at RT for 5 mm before adding (3-chloropyrazin-2-yl)methanamine (1.4 g, 10.0 mmol) and stirring at RT for 18 h. The mixture was partitioned between water and DCM and the combined organic extracts were washed with saturated aqueous NaC1 solution, dried (MgSO4), filtered and evaporated in vacuo. The residue was purified by silica gel chromatography, eluting with 0-50% ethyl acetate in hexane. The residue was dissolved in DCM, washed with water twice, then brine and evaporated in vacuo to give the titlecompound 9B (2.21 g, 67%). ?H NMR (400 MHz, CDC13) oe 8.46 (d, 1H, J = 2.4 Hz), 8.33(m,1H), 8.28 (br s, 1H), 4.75 (d, 2H, J = 5.2 Hz), 3.51 (m, 4H), 3.14 (s, 2H), 2.55 (m, 4H),1.47 (s, 9H).

Reference： [1]Patent: WO2019/46711,2019,A2 .Location in patent: Page/Page column 113; 114

36
[ 156478-71-6 ]
methyl (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxylate hydrochloride [ No CAS ]
tert-butyl 4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-(methoxycarbonyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
27%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 12h;	To a mixture of methyl (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy- pyrrolidine-2-carboxylate (11 g, 37.32 mmol, 1 eq, hydrochloride), 2-(4-tert- butoxycarbonylpiperazin-1-yl)acetic acid (10.03 g, 41.05 mmol, 1.1 eq) in dimethylformamide (400 mL) was added carbonimide hydrochloride (14.31 g, 74.63 mmol, 2 eq), (3545) Hydroxybenzotriazole (6.05 g, 44.78 mmol, 1.2 eq) and Diisopropylethylamine (28.94 g, 223.90 mmol, 6 eq). The mixture stirred at 20 C for 12 h. The mixture was quenched by addition water (1000 mL), extracted with ethyl acetate (100 mL * 6), the combined organic phase washed with brine (100 mL * 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate=3:1~0:1). Compound tert-butyl 4-[2-[[(1S)-1-[(2S,4R)-4-hydroxy-2- methoxycarbonyl-pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethyl]piperazine- 1-carboxylate (5 g, 10.32 mmol, 27% yield) was obtained as a white solid. LC/MS (ESI) m/z: 485.3 [M+1] +.

Reference： [1]Patent: WO2020/51564,2020,A1 .Location in patent: Paragraph 1944; 1945

37
[ 156478-71-6 ]
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-(hydroxymethyl)thiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride [ No CAS ]
tert-butyl 4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-(hydroxymethyl)thiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
340 mg	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 12h;	A solution of (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1S)-1- [4-[4-(hydroxymethyl)thiazol-5-yl]phenyl]ethyl]pyrrolidine-2-carboxamide (351 mg, 0.70 mmol, 1 eq, hydrochloride), <strong>[156478-71-6]2-(4-tert-butoxycarbonylpiperazin-1-yl)acetic acid</strong> (172 mg, 0.70 mmol, 1 eq), hydroxybenzotriazole (114 mg, 0.85 mmol, 1.2 eq), diisopropylethylamine (548 mg, 4.24 mmol, 6 eq), carbodiimide hydrochloride (271 mg, 1.41 mmol, 2 eq) in N, N-dimethyl formamide (20 mL) was stirred at 20 C for 12 h. The reaction solution was washed with water (100 mL). The aqueous layer was extracted with ethyl acetate (40 mL x 8). All the combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue (dichloromethane: methanol = 10:1) was purified by column chromatography on silica gel (ethyl acetate: methanol = 1:0) to give tert-butyl 4-[2-[[(1S)-1- [(2S,4R)-4-hydroxy-2- [[(1S)-1-[4-[4-(hydroxymethyl)thiazol-5- yl]phenyl]ethyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo- ethyl]piperazine-1-carboxylate (340 mg, 0.48 mmol, 68% yield, 97% purity) as a white solid. LC/MS (ESI) m/z: 687.4 [M+1] +.

Reference： [1]Patent: WO2020/51564,2020,A1 .Location in patent: Paragraph 1218; 1219

38
[ 156478-71-6 ]
[ 705941-45-3 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1: hydrogenchloride / water; ethyl acetate / 2 h / 20 °C / Inert atmosphere 2: sodium hydroxide / tetrahydrofuran; water / 2 h / 20 °C / Inert atmosphere

Reference： [1]Current Patent Assignee: UNIVERSITY OF SHEFFIELD - WO2020/99885, 2020, A1

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 156478-71-6 ]

Amides

[ 77279-24-4 ]

tert-Butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate

Similarity: 0.90

[ 200283-08-5 ]

tert-Butyl (2-((tert-butoxycarbonyl)amino)ethyl)(2-hydroxyethyl)carbamate

Similarity: 0.88

[ 234108-58-8 ]

tert-Butyl 4-(2-aminoethyl)-3-oxopiperazine-1-carboxylate

Similarity: 0.86

[ 76003-29-7 ]

1-Boc-3-Oxopiperazine

Similarity: 0.86

[ 219509-79-2 ]

1-tert-Butyl 4-methyl piperazine-1,4-dicarboxylate

Similarity: 0.85

Carboxylic Acids

[ 848482-93-9 ]

(S)-4-(tert-Butoxycarbonyl)piperazine-2-carboxylic acid

Similarity: 0.83

[ 159532-59-9 ]

(S)-1-(tert-Butoxycarbonyl)piperazine-2-carboxylic acid

Similarity: 0.83

[ 278788-60-6 ]

(R)-1-Boc-Piperazine-2-carboxylic acid

Similarity: 0.83

[ 128019-59-0 ]

4-(tert-Butoxycarbonyl)piperazine-2-carboxylic acid

Similarity: 0.83

[ 192330-11-3 ]

(R)-1-Boc-Piperazine-3-carboxylic acid

Similarity: 0.83

Related Parent Nucleus of
[ 156478-71-6 ]

Aliphatic Heterocycles

[ 77279-24-4 ]

tert-Butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate

Similarity: 0.90

[ 234108-58-8 ]

tert-Butyl 4-(2-aminoethyl)-3-oxopiperazine-1-carboxylate

Similarity: 0.86

[ 76003-29-7 ]

1-Boc-3-Oxopiperazine

Similarity: 0.86

[ 219509-79-2 ]

1-tert-Butyl 4-methyl piperazine-1,4-dicarboxylate

Similarity: 0.85

[ 76535-75-6 ]

Di-tert-butyl piperazine-1,4-dicarboxylate

Similarity: 0.85

Piperazines

[ 77279-24-4 ]

tert-Butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate

Similarity: 0.90

[ 234108-58-8 ]

tert-Butyl 4-(2-aminoethyl)-3-oxopiperazine-1-carboxylate

Similarity: 0.86

[ 76003-29-7 ]

1-Boc-3-Oxopiperazine

Similarity: 0.86

[ 219509-79-2 ]

1-tert-Butyl 4-methyl piperazine-1,4-dicarboxylate

Similarity: 0.85

[ 76535-75-6 ]

Di-tert-butyl piperazine-1,4-dicarboxylate

Similarity: 0.85

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 156478-71-6 ] {[proInfo.proName]}

Quality Control of [ 156478-71-6 ]

Related Doc. of [ 156478-71-6 ]

Product Details of [ 156478-71-6 ]

Calculated chemistry of [ 156478-71-6 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 156478-71-6 ]

Application In Synthesis of [ 156478-71-6 ]

[ 156478-71-6 ] Synthesis Path-Upstream 1~3

[ 156478-71-6 ] Synthesis Path-Downstream 1~38

Related Functional Groups of [ 156478-71-6 ]

Amides

Carboxylic Acids

Related Parent Nucleus of [ 156478-71-6 ]

Aliphatic Heterocycles

Piperazines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 156478-71-6 ]

Related Parent Nucleus of
[ 156478-71-6 ]